The US FDA recently approved the combination of dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) for treating BRAFV600E-mutated anaplastic thyroid cancer [37]. Here, MAP2K7 is linked to thyroid gland undifferentiated (anaplastic) carcinoma.